Project Grant R43CA287513
Award Date
8/7/24
Completion Date
7/31/25
Dollars Obligated
$399K
Federal Agency
National Cancer Institute
Awardee
Proton Bio, Inc. (L37UYZG8JMK5)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $800,000 to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The research aims to target the extracellular glucose-regulated protein 78 (eGRP78), which is upregulated in drug-resistant, recurrent brain cancers and plays a key role in tumor growth, immune evasion, and cancer stem cell...
This federal Project Grant award from the National Cancer Institute (93.395 - Cancer Treatment Research) provides funding to Brigham & Women's Hospital Inc. to develop and extensively test a novel cellular therapy platform for treating glioblastoma (GBM), a highly malignant brain tumor. The $417,858 award, effective January 7, 2025 through December 31, 2029, will support the development of engineered mesenchymal stem cells (MSCs) that release bi-specific T-cell engager (BiTE) molecules...
The National Cancer Institute (NCI) awarded a $451,996 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Texas at Arlington (UTA) to establish a high-throughput screening platform for identifying and validating drugs to target migrating and treatment-resistant glioblastoma (GBM) cells. The project aims to develop an ex vivo integrated platform for the quantitative cellular and molecular analysis of therapy-resistant brain cancer cells and their biophysical...
The National Cancer Institute (NCI) has awarded a $609,749 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of North Carolina at Chapel Hill (UNC-CH). The 5-year grant supports the development of a novel combinatorial therapy to improve treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products and services to be delivered under this grant include: Creating an injectable, biodegradable hydrogel...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $447,831 to the University of Colorado-Denver for the development of chimeric antigen receptor (CAR) phagocytes to treat glioblastoma, a type of brain cancer. The project aims to advance novel immunotherapeutic approaches against high-grade gliomas, including glioblastoma multiforme (GBM), anaplastic astrocytoma, and diffuse intrinsic pontine glioma (DIPG) in pediatric patients. This...
The National Cancer Institute (NCI) awarded a $954,000 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh to conduct research targeting glioblastoma stem cells. The research aims to leverage insights from aging in the nervous system and the molecular circuitry of cancer stem cells to understand how aging promotes tumor growth through cell autonomous mechanisms and interactions with the microenvironment. The project will leverage spatial transcriptomics and...
This STTR Phase I award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Immunoblue, LLC for $399,669 aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM). The key products and services to be delivered are: Generating potent and effective patient-derived GBM-specific T cells using a platform that applies Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) to GBM...
The National Cancer Institute (NCI) awarded a $655,306 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Regents of the University of California, San Francisco (UCSF) to investigate targeting reactive metabolite generation as a novel therapeutic approach for isocitrate dehydrogenase (IDH)-mutant gliomas. The key objectives are to determine if combining a glutathione-based glyoxalase 1 (GLO1) inhibitor with radiation therapy is an effective treatment strategy, elucidate the molecular...
The National Cancer Institute (NCI) awarded a $404,974 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The Ohio State University to investigate the potential of KIF20A as a therapeutic target for glioblastoma, an aggressive brain cancer. The two-year grant, effective July 1, 2024, aims to: Define the requirement for KIF20A, a mitotic kinesin, in early mitosis by examining the impact of KIF20A knockout on mitotic progression and factors that influence sensitivity to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a Phase I clinical trial of CAR-T cells engineered to secrete a T cell-engaging antibody molecule (CARV3.TEAM-E cells) for the treatment of glioblastoma (GBM), a deadly brain tumor. The key products and services to be delivered under this $652,725 award, with a project...